An observational study in Sexually Transmitted Disease, Bacterial Vaginosis and Vaginal Candidiasis, sponsored by Janneke van de Wijgert. Completed at 1 site in Rwanda. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-11.
Sponsored by Janneke van de Wijgert · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The current standard of care for urogenital infections in Rwanda is syndromic management. Many urogenital infections are asymptomatic and therefore completely missed, and the management of vaginal discharge syndrome is known to be suboptimal. The primary objective of this study is to evaluate whether it is feasible to improve urogenital infection care in high risk women in Kigali, Rwanda, using point of care (POC) diagnostic testing for HIV, Trichomonas vaginalis (TV), and bacterial vaginosis (BV) in all women; POC testing for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and syphilis in pregnant women and women assessed to be at high risk for these infections using a risk scoring questionnaire; and management of vaginal candidiasis, urinary tract infection (UTI), genital ulcers/inguinal bubos, and lower abdominal pain in women reporting relevant symptoms. The secondary objectives of this study are 1) to evaluate the performance and 2) to obtain the opinions of Rwandan stakeholders.
This is a cross-sectional study. The improved urogenital infection care services will be advertised to women in Kigali, Rwanda, targeting women with urogenital complaints as well as women without urogenital complaints who have had high risk behavior. The services will be available for free at the research clinic for the duration of the project. All consenting women who attend the research clinic during the study period will be offered:
Information about sociodemographics, risk behavior, sexual and reproductive health history and current urogenital symptoms will be collected during the clinic visit. Women can opt out of each service offered. Services will be delivered within one half day. However, women can choose to leave before all results are available, and be contacted by study staff when results are available, which is particularly relevant for women undergoing CT/NG POC testing (which takes about 90 minutes).
Vaginal swabs for storage will be taken from all consenting women (women can choose between self- or clinician-sampling) for additional research testing at the end of the study to allow for performance evaluation of the CT/NG, TV and BV POC tests.
Opinions of stakeholders will be gathered during workshops (one before and one after completion of the study) and in-depth interviews (IDIs).
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
This study's enrollment of 705 is above the median of 578 across 93 observational studies indexed under Sexually Transmitted Diseases.
Browse Sexually Transmitted Diseases studies →Janneke van de Wijgert is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant will not be excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
Diagnostic Test: Urogenital infection point-of-care tests
Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators)
Clinical monitoring and evaluation indicators: numbers of women with positive CT/NG or syphilis risk scores, number of pelvic exams done, etc (see row titles in the table)
Time frame: Each participant was assessed at one main study visit, which lasted up to 4 hours.
Feasibility of Integrating Point-of-care Testing (Client Satisfaction Surveys)
Answers to questions about experiences with the procedures (client satisfaction survey).
Time frame: Each client satisfaction survey was conducted at a main visit and lasted up to 30 min.
Performance of Syndromic Management With or Without Integration of Point-of-care Tests
With performance we mean sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). We determined the number of women who would have received treatment for BV, VVC, TV, NG, and/or CT in the following situations: 1) if we would have followed the WHO syndromic management algorithms for vaginal discharge and lower abdominal pain; and 2) based on the POCT-based WISH algorithms (this is what we did in real life during the study), and compared each of these with gold standard infection-specific diagnoses. The results of the first comparison are reported in the first column and results of the second comparison in the second column.
Time frame: Each participant was assessed at one main study visit, which lasted up to 4 hours.
At risk women regardless of symptoms were enrolled between 7-2016 and 3-2017. Recruitment activities were implemented by study staff with the help of community mobilizers. They organized recruitment meetings, and distributed flyers. Women were encouraged to refer their friends.
| Milestone | Women at Risk of Urogenital Infections. |
|---|---|
| Started | 705 |
| Attended an additional visit (if needed) | 51 |
| Completed | 705 |
| Not completed | 0 |
Clinical monitoring and evaluation indicators: numbers of women with positive CT/NG or syphilis risk scores, number of pelvic exams done, etc (see row titles in the table)
| Participants | Women at Risk of Urogenital Infections. |
|---|---|
| Had a positive CT/NG risk score | 396 |
| Had a positive syphilis risk score | 378 |
| Underwent a pelvic examination | 399 |
| Had any abnormality during the pelvic examination | 216 |
| Had at least one positive POCT result | 541 |
| Received all positive POCT results at main visit | 505 |
| Received inadequate treatment | 0 |
| Needed and received a referral | 79 |
| Had at least one partner requiring notification | 201 |
| Required at least one additional visit | 51 |
Answers to questions about experiences with the procedures (client satisfaction survey).
| Participants | Women at Risk of Urogenital Infections. |
|---|---|
| Felt welcome at study clinic | 107 |
| Thought medical services were of good quality | 107 |
| Thought counselling was of good quality | 107 |
| Thought visit duration was too long but worth it | 41 |
| Thought visit duration was too long and not worth | 0 |
| Willing to be tested in future even if asymptomati | 100 |
| Willing to pay for services in future | 95 |
With performance we mean sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). We determined the number of women who would have received treatment for BV, VVC, TV, NG, and/or CT in the following situations: 1) if we would have followed the WHO syndromic management algorithms for vaginal discharge and lower abdominal pain; and 2) based on the POCT-based WISH algorithms (this is what we did in real life during the study), and compared each of these with gold standard infection-specific diagnoses. The results of the first comparison are reported in the first column and results of the second comparison in the second column.
| % (sensitivity/specificity/PPV/NPV) | WHO Syndromic Management (Entire Study Population) | WISH (Entire Study Population) |
|---|---|---|
| Chlamydia sensitivity | 58.3 (45.5 to 70.2) | 71.7 (58.3 to 81.7) |
| Chlamydia specificity | 44.7 (40.8 to 48.5) | 100 (100 to 100) |
| Chlamydia PPV | 8.9 (6.5 to 12.1) | 100 (100 to 100) |
| Chlamydia NPV | 92 (88.4 to 94.6) | 97.4 (95.9 to 98.4) |
| Gonorrhea sensitivity | 66.0 (51.8 to 77.8) | 76.0 (62.2 to 85.9) |
| Gonorrhea specificity | 45.2 (41.4 to 49.0) | 100 (100 to 100) |
| Gonorrhea PPV | 8.4 (6.0 to 11.6) | 100 (100 to 100) |
| Gonorrhea NPV | 94.6 (91.4 to 96.6) | 98.2 (96.9 to 99.0) |
| Trichomonas vaginalis sensitivity | 60.4 (50.9 to 69.1) | 68.5 (59.2 to 76.5) |
| Trichomonas vaginalis specificity | 45.6 (41.6 to 49.7) | 97.4 (95.7 to 98.4) |
| Trichomonas vaginalis PPV | 17.5 (14.0 to 21.7) | 83.5 (74.4 to 89.8) |
| Trichomonas vaginalis NPV | 85.7 (81.3 to 89.2) | 94.2 (92.0 to 95.8) |
| Bacterial vaginosis sensitivity | 61.6 (52.7 to 69.7) | 95.2 (89.7 to 97.8) |
| Bacterial vaginosis specificity | 46.0 (41.9 to 50.2) | 41.2 (37.2 to 45.4) |
| Bacterial vaginosis PPV | 20.2 (16.4 to 24.5) | 26.4 (22.5 to 30.7) |
| Bacterial vaginosis NPV | 84.4 (79.9 to 88.1) | 97.5 (94.5 to 98.9) |
| Vulvovaginal candidiasis sensitivity | 74.6 (61.9 to 84.1) | 64.4 (51.4 to 75.6) |
| Vulvovaginal candidiasis specificity | 50.6 (46.6 to 54.5) | 69.4 (65.7 to 72.9) |
| Vulvovaginal candidiasis PPV | 12.4 (9.3 to 16.2) | 16.5 (12.2 to 21.8) |
| Vulvovaginal candidiasis NPV | 95.5 (92.7 to 97.3) | 95.4 (93.1 to 97.0) |
Collected over Each participant was assessed at one main study visit, which lasted up to 4 hours.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Women at Risk of Urogenital Infections. | 0/705 (0%) | 0/705 (0%) | 2/705 (0.3%) |
| Event | Women at Risk of Urogenital Infections. |
|---|---|
| Allergic reaction to metronidazoleSkin and subcutaneous tissue disorders | 2/705 |
All 705 women who attended a main visit. Women were aged 18 or older, and at risk of sexually transmitted infections (more than one sex partner and/or having been treated for at least one STI in the past year), with or without urogenital symptoms. HIV-positive and pregnant women were not excluded.
| Age, Categorical(Participants) | Women at Risk of Urogenital Infections. |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 705 |
| >=65 years | 0 |
| Age, Continuous(years) | Women at Risk of Urogenital Infections. |
|---|---|
| Mean | 32.9 (18 to 62) |
| Sex: Female, Male(Participants) | Women at Risk of Urogenital Infections. |
|---|---|
| Female | 705 |
| Male | 0 |
| Race and Ethnicity Not Collected(Participants) | Women at Risk of Urogenital Infections. |
|---|
| Race/Ethnicity, Customized(Participants) | Women at Risk of Urogenital Infections. |
|---|---|
| African (Rwandan) | 705 |
| Region of Enrollment(participants) | Women at Risk of Urogenital Infections. |
|---|---|
| Rwanda | 705 |
| Chlamydia trachomatis positive by gold standard test(Participants) | Women at Risk of Urogenital Infections. |
|---|---|
| Count of participants | 60 |
| Neisseria gonorrhoeae positive by gold standard test(Participants) | Women at Risk of Urogenital Infections. |
|---|---|
| Count of participants | 50 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — The University of Liverpool and project investigators support open access but university-wide systems are not yet accessible and open access has not yet been negotiated with the Rwandan authorities.
Ran from Jul 2016 to primary completion in Mar 2017, 8 months.
Results were first posted in Sep 2019, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →
Janneke van de Wijgert